Wuhan Historical Income Statement

300871 Stock

11.40 0.01 0.09%

Historical analysis of Wuhan Hvsen income statement accounts such as Other Operating Expenses of 5.6 M, Net Income Applicable To Common Shares of 96.4 M or Income Tax Expense of 4.4 M can show how well Wuhan Hvsen Biotechnology performed in making a profits. Evaluating Wuhan Hvsen income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Wuhan Hvsen's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Wuhan Hvsen Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Wuhan Hvsen Biotechnology is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Wuhan Income Statement Analysis

Wuhan Hvsen Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Wuhan Hvsen shareholders. The income statement also shows Wuhan investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Wuhan Hvsen Income Statement Chart

At present, Wuhan Hvsen's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Net Income Applicable To Common Shares is expected to grow to about 96.4 M, whereas Other Operating Expenses is forecasted to decline to about 5.6 M.

Other Operating Expenses Income Tax Expense Selling General Administrative Total Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Wuhan Hvsen Biotechnology. It is also known as Wuhan Hvsen overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Revenue

Total revenue comprises all receipts Wuhan Hvsen Biotechnology generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from Wuhan Hvsen's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Wuhan Hvsen Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2023	2024 (projected)
Minority Interest	17.0K	14.4K
Income Tax Expense	4.6M	4.4M

Minority Interest Income Tax Expense

Wuhan Hvsen income statement Correlations

	Other Operating Expenses	Income Tax Expense	Minority Interest	Tax Provision	Net Interest Income	Interest Income	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Net Income
Other Operating Expenses		-0.26	0.81	-0.7	-0.77	0.49	0.56	0.81	0.22	-0.53	-0.56	-0.41	0.78	0.41	0.85	0.85	0.77	-0.59	-0.56
Income Tax Expense	-0.26		0.16	0.75	0.63	0.43	0.23	0.04	0.57	0.88	0.85	0.8	0.0	0.51	-0.03	-0.05	-0.42	0.84	0.85
Minority Interest	0.81	0.16		-0.47	-0.55	0.59	0.39	0.71	0.29	-0.24	-0.3	-0.13	0.72	0.5	0.73	0.73	0.59	-0.33	-0.3
Tax Provision	-0.7	0.75	-0.47		0.97	-0.06	-0.13	-0.44	0.19	0.87	0.96	0.63	-0.48	0.03	-0.51	-0.52	-0.86	0.98	0.96
Net Interest Income	-0.77	0.63	-0.55	0.97		-0.2	-0.3	-0.56	0.01	0.76	0.91	0.49	-0.56	-0.16	-0.61	-0.62	-0.94	0.92	0.91
Interest Income	0.49	0.43	0.59	-0.06	-0.2		0.83	0.89	0.88	0.31	0.2	0.47	0.87	0.94	0.85	0.84	0.47	0.15	0.2
Selling General Administrative	0.56	0.23	0.39	-0.13	-0.3	0.83		0.84	0.86	0.18	0.06	0.41	0.77	0.9	0.79	0.8	0.56	0.03	0.06
Total Revenue	0.81	0.04	0.71	-0.44	-0.56	0.89	0.84		0.67	-0.12	-0.21	0.06	0.98	0.8	1.0	0.99	0.73	-0.25	-0.21
Gross Profit	0.22	0.57	0.29	0.19	0.01	0.88	0.86	0.67		0.59	0.39	0.76	0.6	0.95	0.6	0.59	0.31	0.36	0.39
Operating Income	-0.53	0.88	-0.24	0.87	0.76	0.31	0.18	-0.12	0.59		0.93	0.88	-0.18	0.41	-0.21	-0.22	-0.55	0.92	0.93
Net Income From Continuing Ops	-0.56	0.85	-0.3	0.96	0.91	0.2	0.06	-0.21	0.39	0.93		0.72	-0.24	0.25	-0.28	-0.29	-0.74	1.0	1.0
Ebit	-0.41	0.8	-0.13	0.63	0.49	0.47	0.41	0.06	0.76	0.88	0.72		0.03	0.63	-0.03	-0.04	-0.2	0.71	0.72
Research Development	0.78	0.0	0.72	-0.48	-0.56	0.87	0.77	0.98	0.6	-0.18	-0.24	0.03		0.75	0.98	0.98	0.73	-0.28	-0.24
Ebitda	0.41	0.51	0.5	0.03	-0.16	0.94	0.9	0.8	0.95	0.41	0.25	0.63	0.75		0.74	0.74	0.46	0.21	0.25
Cost Of Revenue	0.85	-0.03	0.73	-0.51	-0.61	0.85	0.79	1.0	0.6	-0.21	-0.28	-0.03	0.98	0.74		1.0	0.75	-0.32	-0.28
Total Operating Expenses	0.85	-0.05	0.73	-0.52	-0.62	0.84	0.8	0.99	0.59	-0.22	-0.29	-0.04	0.98	0.74	1.0		0.76	-0.34	-0.29
Reconciled Depreciation	0.77	-0.42	0.59	-0.86	-0.94	0.47	0.56	0.73	0.31	-0.55	-0.74	-0.2	0.73	0.46	0.75	0.76		-0.77	-0.74
Income Before Tax	-0.59	0.84	-0.33	0.98	0.92	0.15	0.03	-0.25	0.36	0.92	1.0	0.71	-0.28	0.21	-0.32	-0.34	-0.77		1.0
Net Income	-0.56	0.85	-0.3	0.96	0.91	0.2	0.06	-0.21	0.39	0.93	1.0	0.72	-0.24	0.25	-0.28	-0.29	-0.74	1.0

Click cells to compare fundamentals

Wuhan Hvsen Account Relationship Matchups

Wuhan Hvsen income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	5.2M	2.3M	2.9M	18.4M	28.2M	29.6M
Other Operating Expenses	3.9M	4.4M	4.9M	8.8M	10.2M	5.6M
Net Income Applicable To Common Shares	68.8M	150.2M	132.9M	52.7M	60.6M	96.4M
Income Tax Expense	9.8M	25.9M	18.0M	4.0M	4.6M	4.4M
Tax Provision	9.8M	25.9M	18.0M	4.0M	(4.3M)	(4.1M)
Net Interest Income	(4.5M)	3.9M	4.4M	(14.1M)	(24.3M)	(23.0M)
Interest Income	2.0M	6.5M	7.7M	4.8M	4.3M	4.4M
Selling General Administrative	16.1M	66.3M	64.5M	59.5M	66.2M	52.6M
Total Revenue	427.2M	777.5M	996.2M	1.0B	1.0B	796.0M
Gross Profit	163.7M	287.9M	270.7M	225.4M	213.3M	243.2M
Operating Income	82.2M	178.0M	136.2M	79.3M	41.9M	82.1M
Net Income From Continuing Ops	68.8M	150.2M	132.9M	52.7M	16.8M	15.9M
Ebit	72.9M	162.4M	135.3M	61.0M	70.2M	111.9M
Research Development	21.1M	28.4M	46.9M	40.1M	44.6M	34.5M
Ebitda	100.4M	197.4M	182.2M	137.7M	158.3M	152.5M
Cost Of Revenue	263.5M	489.6M	725.5M	797.5M	806.5M	552.8M
Total Operating Expenses	343.9M	599.4M	860.0M	943.6M	977.8M	682.8M
Reconciled Depreciation	12.5M	19.1M	28.5M	62.6M	120.4M	126.4M
Income Before Tax	78.6M	176.0M	150.8M	56.7M	12.4M	11.8M
Net Income	68.8M	150.2M	132.9M	52.7M	16.8M	15.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in Wuhan Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Wuhan Historical Income Statement

About Wuhan Income Statement Analysis

Wuhan Hvsen Income Statement Chart

Other Operating Expenses

Total Revenue

Wuhan Hvsen income statement Correlations

Wuhan Hvsen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Wuhan Hvsen income statement Accounts

Also Currently Popular

Other Information on Investing in Wuhan Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Total Revenue
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Total Operating Expenses	+ 1.0	Cost Of Revenue
Net Income	+ 1.0	Income Before Tax
Total Operating Expenses	+ 0.99	Total Revenue

Reconciled Depreciation	- 0.94	Net Interest Income
Reconciled Depreciation	- 0.86	Tax Provision
Income Before Tax	- 0.77	Reconciled Depreciation
Net Interest Income	- 0.77	Other Operating Expenses
Net Income	- 0.74	Reconciled Depreciation
Reconciled Depreciation	- 0.74	Net Income From Continuing Ops